Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years

Key Points

• This research aims to evaluate the long-term effectiveness and safety of avapritinib in treating chronic indolent systemic mastocytosis.
• Conducted a long-term follow-up study
• Included patients with chronic indolent systemic mastocytosis
• Assessed the effectiveness and safety of avapritinib over three years
• Avapritinib demonstrated effective long-term disease control
• Well-tolerated with a favorable safety profile
• Shows a positive benefit-risk balance for ongoing treatment